Universitätsklinikum Tulln

Background: Interpersonal emotion regulation (iER) is the process of managing others’ emotions and is critical during early adolescence, when social awareness and peer dependence increase. Little is known about how sex and gender role orientation shape adolescents’ iER. This study examined whether early adolescents differ in their use of person-focused (acceptance) versus problem-focused (positive engagement) strategies and whether these differences depend on context and measurement method. Methods: Data were collected from 322 adolescents (141 girls, 181 boys; aged 10–14 years, M = 12.47, SD = 1.55). The cross-sectional online study used a multi-method design comprising open-ended visual vignettes, a standardised questionnaire, and a serious game task. Participants also completed a validated gender-role self-concept measure assessing femininity and masculinity. Analyses were conducted using Poisson and logistic regressions with sex, femininity, and masculinity as predictors. Results: Across tasks, adolescents preferred problem-focused over person-focused strategies. Girls and those higher in femininity reported or generated more acceptance-based strategies, whereas boys and those higher in masculinity favoured positive engagement. These effects were evident in reflective measures (vignettes and questionnaire) but not in the interactive game, where sex and gender differences were absent. Conclusions: Findings suggest that gendered socialisation processes shape how adolescents regulate others’ emotions, particularly when behaviour is consciously reported. However, in ecologically valid contexts, these differences diminish, indicating shared capacities for adaptive interpersonal regulation across genders.

Zusammenfassung Integrative Therapie (IT) entwickelt seit den 1960er-Jahren ein multimodales Behandlungsmodell, das unterschiedliche Therapieschulen in einem konsistenten Rahmen verbindet. Eine naturalistische Studie mit Psy-III-Ärzt:innen zeigt deutliche und nachhaltige Verbesserungen depressiver und ängstlicher Symptome. Die Ergebnisse belegen hohe und stabile Wirksamkeit der IT unter realen Versorgungsbedingungen.

<title>Abstract</title> While genomic testing is increasingly utilised to personalise cancer treatment, its complexity creates challenges in achieving informed consent. Partnering with patients, carers, researchers and health professionals, we developed a Question Prompt List (QPL) aiming to support communication and informed consent for tumour profiling and genomic research in oncology. Participants (n = 38) included cancer patients participating (or not) in genomic research, carers, researchers and clinicians. Two rounds of interviews elicited information needs and suggested questions, followed by feedback on the draft QPL and its potential value. We produced concise answers for all questions, edited wording using health literacy principles, and refined according to feedback. The QPL includes 29 items arranged into three sections: Comprehensive Genomic Profiling (CGP), Results of CGP, and About the Genomic Research Study. Participants believed the QPL would empower patients and carers, support clinicians and researchers to engage with patient/family queries, and enable better informed consent in genomic oncology. The Consent in Genomic Testing (CoGenT) Question Prompt List, including evidence-based answers, has been developed rigorously and collaboratively. This simple and flexible tool is perceived as acceptable and useful for patients, carers, clinicians, and research personnel engaging in informed consent for genomic research including tumour profiling.

Ochratoxin A (OTA) is a nephrotoxic and hepatotoxic mycotoxin commonly found in animal feed, posing health risks to dairy cattle and potential contamination of dairy products. This study examined the effects of short-term (7-day) dietary OTA exposure on dairy cow health and the distribution of OTA and its metabolite ochratoxin α (OTα) across different biological matrices, including plasma, serum, milk, urine, and faeces. Twelve Simmental cows were randomly allocated into two groups receiving either a low (LD, 5 mg/cow/day) or a high (HD, 50 mg/cow/day) OTA dose. Cows were monitored for health parameters including blood chemistry and haematology, chewing, milk and faecal parameters, as well as for the kinetics of OTA from feed to blood, urine, milk and faeces. OTA and OTα were analysed using HPLC-MS. No significant health effects were observed, except for a slight decrease in faecal scores (LD: 2.72 vs. HD: 2.35) and an increase in chewing activity in the HD group (LD: 53.3 vs. HD: 59,9), both within normal ranges. Plasma and serum OTA and OTα levels stabilised after 60 h of exposure, with OTα dominating in faeces and urine, indicating efficient metabolism. OTA was not detected in milk. The results suggest that daily OTA exposure up to 50 mg per cow for seven days does not harm cow health or contaminate milk.

Disease-modifying therapies with amyloid-antibodies will soon be available for patients with early Alzheimer's disease, which necessitates diagnostic and therapeutic resources in hospital and outpatient settings. The Austrian Alzheimer Society developed an online questionnaire to survey Austrian hospital-based departments of neurology and psychiatry regarding resources for amyloid-antibody therapies. Between May and October 2023, 30out of 41neurology (73%) and 12out of 33psychiatry departments (36%) responded. The number of first examinations per year and center ranges between0 in centers accepting only secondary referrals and 500, median 100. Of the patients 30% (median; range 0-80%) achieve amini-mental state examination sum score ≥ 22 constituting an early disease stage. First visits comprise medical history, clinical examination, routine blood sampling and neurocognitive screening in 90-100% of patients, magnetic resonance imaging in90% (median; range 10-100%), amyloid-PET in 5% (0-70%), cerebrospinal fluid analysis (Aß42, Aß40, tau, phospho-tau) in 25% (0-90%) and Apo‑E testing in 2.5% (0-100%). To assess the amyloid status 18centers (44%) prefer amyloid-PET to lumbar puncture, 20 (49%) vice versa and 15 centers intend to offer amyloid-antibody therapy. Differences between centers and federal states were observed regarding hospital-based resources for amyloid-antibody therapies. Asubstantial need exists for early dementia diagnosis, medical, neuropsychological, nursing and administrative resources, adequate space, access to amyloid-PET and MRI. All centers highlighted the need for structured patient pathways and multidisciplinary care networks, including neurologists, psychiatrists, radiologists, neuropsychologists operating in clinical practice, rehabilitation and dementia care settings.

ABSTRACTObjectivesTo develop and validate educational clinical vignettes (CVs) based on real-life patients with serious pathology from the disciplines of oncology, internal medicine and orthopaedics that are relevant for physiotherapists (PTs) working in a non-direct access system.DesignA mixed-methods study using an iterative design was employed to develop and validate CVs that focused on serious pathology.SettingAcademic and clinical settings within health faculties at three universities in Austria and the UK.ParticipantsMedical doctors (MD) (n=3) and PTs (n=4) developed CVs in the disciplines of internal medicine, oncology and orthopaedics. Validation of the CVs was undertaken in three stages: internal validation by the research team (n=7), external validation by MDs (n=3) and external validation by PTs (n=18).Results25 CVs focusing on internal medicine (9), oncology (8) and orthopaedics (8) were developed. Results of the consensus method of Haute Autorité de Santé ranged between 7 and 9 in the internal validation stage. In the external validation stage with MDs, one orthopaedic CV was excluded, resulting in a final total of 24 validated CVs.ConclusionsThis is the first time educational CVs have been developed and validated across such a broad range of pathologies for countries without direct access to physiotherapy, for use in the education of PTs. Furthermore, the approach described in the Methods section of this paper may serve as a template in similar future projects.

Zusammenfassung Die Adoleszenz ist durch eine Vielzahl entwicklungspsychologischer Herausforderungen gekennzeichnet, die bereits für psychisch gesunde Menschen eine große Belastung darstellen können. Da herkömmliche Versorgungssysteme den Bedürfnissen psychiatrischer Patient:innen im Übergang ins Erwachsenenalter oft nicht gerecht werden, entstehen zunehmend spezialisierte psychiatrische Angebote für diese Altersgruppe. Ein besonders kritischer Punkt ist dabei der Wechsel zwischen Kinder- und Jugendpsychiatrie (KJP) und Erwachsenenpsychiatrie (EP), der häufig mit Unsicherheiten verbunden ist und nicht selten zu Therapieabbrüchen führt. Der folgende Beitrag stellt das psychiatrische Versorgungssystem des UK Tulln rund um das Transitionsalter vor, das versucht, dieser Problematik durch eine enge und kontinuierliche Zusammenarbeit der beiden Fachabteilungen zu begegnen und auch im jungen Erwachsenenalter verschiedene altersadäquate Behandlungsoptionen bietet. Im vorliegenden Artikel wird weiters der Fall eines 21-jährigen Patienten mit Autismus-Spektrum-Störung und rezidivierender depressiver Störung präsentiert, anhand dessen die Relevanz vielfältiger und flexibel eingesetzter Behandlungsoptionen deutlich wird.